Agios Pharmaceuticals, Inc. (NASDAQ:AGIO) Given Consensus Rating of “Moderate Buy” by Analysts

Shares of Agios Pharmaceuticals, Inc. (NASDAQ:AGIO) have been given a consensus rating of “Moderate Buy” by the eight analysts that are covering the stock, Marketbeat reports. Four analysts have rated the stock with a hold recommendation and four have issued a buy recommendation on the company. The average 1-year price target among analysts that have issued ratings on the stock in the last year is $56.33.

AGIO has been the subject of several recent analyst reports. Royal Bank of Canada upped their price objective on shares of Agios Pharmaceuticals from $55.00 to $57.00 and gave the stock an “outperform” rating in a research report on Tuesday, December 10th. Scotiabank boosted their price objective on Agios Pharmaceuticals from $53.00 to $75.00 and gave the stock a “sector outperform” rating in a research report on Monday, December 9th. Raymond James reaffirmed an “outperform” rating and set a $51.00 price target on shares of Agios Pharmaceuticals in a research note on Thursday, October 10th. StockNews.com raised Agios Pharmaceuticals from a “sell” rating to a “hold” rating in a research report on Saturday, November 9th. Finally, Cantor Fitzgerald reiterated an “overweight” rating on shares of Agios Pharmaceuticals in a research report on Wednesday, December 18th.

Agios Pharmaceuticals Stock Up 0.5 %

Shares of Agios Pharmaceuticals stock opened at $33.73 on Thursday. The stock has a market capitalization of $1.92 billion, a price-to-earnings ratio of 2.97 and a beta of 0.87. The company has a 50-day simple moving average of $41.15 and a two-hundred day simple moving average of $44.56. Agios Pharmaceuticals has a twelve month low of $22.23 and a twelve month high of $62.58.

Insider Activity at Agios Pharmaceuticals

In other Agios Pharmaceuticals news, insider Tsveta Milanova sold 2,804 shares of Agios Pharmaceuticals stock in a transaction on Monday, January 6th. The shares were sold at an average price of $32.18, for a total value of $90,232.72. Following the completion of the sale, the insider now directly owns 18,906 shares of the company’s stock, valued at approximately $608,395.08. The trade was a 12.92 % decrease in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which is accessible through this hyperlink. 4.93% of the stock is owned by corporate insiders.

Institutional Trading of Agios Pharmaceuticals

Hedge funds and other institutional investors have recently added to or reduced their stakes in the company. Wingate Wealth Advisors Inc. acquired a new stake in Agios Pharmaceuticals in the fourth quarter valued at approximately $53,000. KBC Group NV lifted its holdings in shares of Agios Pharmaceuticals by 30.5% in the 4th quarter. KBC Group NV now owns 2,615 shares of the biopharmaceutical company’s stock worth $86,000 after purchasing an additional 611 shares in the last quarter. Mirae Asset Global Investments Co. Ltd. grew its position in Agios Pharmaceuticals by 21.4% in the 3rd quarter. Mirae Asset Global Investments Co. Ltd. now owns 2,058 shares of the biopharmaceutical company’s stock valued at $94,000 after purchasing an additional 363 shares during the period. CWM LLC raised its holdings in Agios Pharmaceuticals by 554.7% during the third quarter. CWM LLC now owns 2,167 shares of the biopharmaceutical company’s stock worth $96,000 after buying an additional 1,836 shares during the last quarter. Finally, Quest Partners LLC lifted its stake in shares of Agios Pharmaceuticals by 139.6% in the third quarter. Quest Partners LLC now owns 2,202 shares of the biopharmaceutical company’s stock valued at $98,000 after buying an additional 1,283 shares in the last quarter.

About Agios Pharmaceuticals

Agios Pharmaceuticals, Inc, a biopharmaceutical company, discovers and develops medicines in the field of cellular metabolism in the United States. Its lead product includes PYRUKYND (mitapivat), an activator of wild-type and mutant pyruvate kinase (PK), enzymes for the treatment of hemolytic anemias.